{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"groups":[{"description":"This cohort received Zoledronic Acid 4 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.","id":"OG000","title":"Zoledronic Acid 4 mg Q4W / Denosumab 120 mg Q4W"},{"description":"This cohort received Denosumab 120 mg Q4W in the blinded treatment phase of the parent study 20050103 (NCT00321620) or 20050136 (NCT00321464), and received Denosumab 120 mg Q4W in this open-label extension study.","id":"OG001","title":"Denosumab 120 mg Q4W / Denosumab 120 mg Q4W"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants Survived","type":"PRIMARY","unitOfMeasure":"Participants"}